Traws Pharma (FRA:0T20) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0T20 Traws Pharma Inc FRA:0T20
44 GF Score
Price €6.60
GF Value €121.46
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:0T20 vs ICU, INAB, CALC: Short Interest Comparison

For the Biotechnology subindustry, Traws Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Short Interest falls into.


FRA:0T20
44GF Score
Traws Pharma Inc FRA:0T20
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Traws Pharma (FRA:0T20) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of €6.60 is trading 94.6% below its estimated GF Value™ of €121.46.

Key valuation signals for FRA:0T20:

  • Short Interest:
  • GF Value™: €121.46 vs. price of €6.60 (94.6% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the FRA:0T20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Other Exchanges TRAW:USA
Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
44GF Score

Get the complete analysis for FRA:0T20

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€121.46
GF Value